The estimated Net Worth of Pharmaceutical Inc Biomarin is at least $41.5 million dollars as of 8 December 2012. Pharmaceutical Biomarin owns over 5,000,000 units of La Jolla Pharmaceutical Co stock worth over $41,466,669 and over the last 16 years Pharmaceutical sold LJPC stock worth over $0.
Pharmaceutical has made over 1 trades of the La Jolla Pharmaceutical Co stock since 2012, according to the Form 4 filled with the SEC. Most recently Pharmaceutical bought 5,000,000 units of LJPC stock worth $3,750,000 on 8 December 2012.
The largest trade Pharmaceutical's ever made was buying 5,000,000 units of La Jolla Pharmaceutical Co stock on 8 December 2012 worth over $3,750,000. On average, Pharmaceutical trades about 1,666,667 units every 0 days since 2009. As of 8 December 2012 Pharmaceutical still owns at least 6,666,667 units of La Jolla Pharmaceutical Co stock.
You can see the complete history of Pharmaceutical Biomarin stock trades at the bottom of the page.
Pharmaceutical's mailing address filed with the SEC is 105 DIGITAL DRIVE, , NOVATO, CA, 94949.
Over the last 21 years, insiders at La Jolla Pharmaceutical Co have traded over $13,460,170 worth of La Jolla Pharmaceutical Co stock and bought 11,640,515 units worth $137,250,039 . The most active insiders traders include Advisors Llcperceptive Life..., James N Topper et Woodlands Health Ventures F.... On average, La Jolla Pharmaceutical Co executives and independent directors trade stock every 63 days with the average trade being worth of $1,249,971. The most recent stock trade was executed by Craig A Johnson on 8 July 2022, trading 12,000 units of LJPC stock currently worth $47,160.
La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.
La Jolla Pharmaceutical Co executives and other stock owners filed with the SEC include: